Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the treatment of obesity. The objective of this dose-ranging study is to support dose selection for Phase 3, and to inform the ongoing development of a convenient delivery system for this combination regimen.
Read More...
[Source: Obesity / Weight Loss / Fitness News From Medical News Today - Posted by FreeAutoBlogger]
0 comments:
Post a Comment